4.8 Article

Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387

期刊

EMBO JOURNAL
卷 36, 期 2, 页码 202-212

出版社

WILEY-BLACKWELL
DOI: 10.15252/embj.201694834

关键词

negative regulation; STAT2; T387 phosphorylation; type I interferon

资金

  1. National Institutes of Health [PO1 CA062220]
  2. National Natural Science Foundation of China [31571439]
  3. Ocean University of China Zhufeng Talented Professionals start-up fund
  4. NIH [1S10RR031537-01]
  5. NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER
  6. NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR031537] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The transcription factor ISGF3, comprised of IRF9 and tyrosine-phosphorylated STATs 1 and 2, transmits the signal from the type I interferon receptor to the genome. We have discovered a novel phosphorylation of STAT2 on T387 that negatively regulates this response. In most untreated cell types, the majority of STAT2 is phosphorylated on T387 constitutively. In response to interferon-, the T387A mutant of STAT2 is much more effective than wild-type STAT2 in mediating the expression of many interferon-stimulated genes, in protecting cells against virus infection, and in inhibitingcell growth. Interferon--treated cells expressing wild-type STAT2 contain much less ISGF3 capable of binding to an interferon-stimulated response element than do cells expressing T387A STAT2. T387 lies in a cyclin-dependent kinase (CDK) consensus sequence, and CDK inhibitors decrease T387 phosphorylation. Using CDK inhibitors to reverse the constitutive inhibitory phosphorylation of T387 of U-STAT2 might enhance the efficacy of type I interferons in many different clinical settings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据